deepali kumar - Infectious Diseases

Author Information

Deepali Kumar is a renowned expert in the field of Transplant Infectious Diseases, holding a key position at the Multi-Organ Transplant Program at the University Health Network in Toronto, Canada. Her research primarily focuses on the intersection of infectious diseases and organ transplantation, addressing critical challenges in this specialized medical domain. Her work is pivotal in understanding and improving health outcomes for transplant recipients, especially in the context of infectious disease management and prevention.

Research Contributions

Dr. Kumar's research contributions are extensive and impactful, particularly in the area of infectious diseases affecting organ transplant recipients. Her recent studies have explored various critical topics such as the molecular identification of pathogens like Aspergillus fumigatus in lung transplant recipients, the impact of COVID-19 vaccination and monoclonal antibody therapy on organ transplant recipients, and the immune response to delayed-interval COVID-19 vaccination. Additionally, she has studied the efficacy of combining antiviral treatments for severe influenza and examined vaccination strategies in transplant settings. Her work is instrumental in guiding clinical practices and policies related to infectious diseases in transplant medicine.

Aliases

The information provided does not list any aliases for Deepali Kumar. Therefore, she appears to publish under her full name consistently.

Publication and Citation Metrics

Metric	Value
Citation Count	12,720
h-index	61
Paper Count	273
Affiliation	Transplant Infectious Diseases and Multi-Organ Transplant Program, University Health Network, PMB 11-174, 585 University Avenue, Toronto, ON, M5G 2N2, Canada.

Publications:

Molecular identification of Aspergillus fumigatus complex from lung transplant recipients using multilocus sequencing analysis (MLSA)

DOI: 10.3138/jammi-2021-0004

Year: 2022

Impact of Vaccination and Early Monoclonal Antibody Therapy on COVID-19 Outcomes in Organ Transplant Recipients During the Omicron Wave.

DOI: 10.1093/cid/ciac324

Year: 2022

Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses.

DOI: 10.1038/s41590-021-01126-6

Year: 2022

Survey of Current Transplant Center Practices Regarding COVID-19 Vaccine Mandates in the United States.

DOI: 10.1111/ajt.16995

Year: 2022

Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial.

DOI: 10.1016/s1473-3099(21)00469-2

Year: 2022

Neutralization against Omicron variant in transplant recipients after three-doses of mRNA vaccine.

DOI: 10.1111/ajt.17020

Year: 2022

Evaluating the Role of STAT3 in CD4+ T Cells in Susceptibility to Invasive Aspergillosis

DOI: 10.1128/IAI.00035-21

Year: 2021

Ex vivo Treatment of Cytomegalovirus in Human Donor Lungs Using a Novel Chemokine-Based Immunotoxin

DOI: 10.1016/j.healun.2021.10.010

Year: 2021

Vaccination Strategies in Solid Organ and Stem Cell Transplant

DOI: 10.1007/978-3-030-25869-6_11

Year: 2021

The value of open-source clinical science in pandemic response: lessons from ISARIC

DOI: 10.1016/S1473-3099(21)00565-X

Year: 2021

What is Pink Eye?

How Does Lipid Metabolism Influence Pathogen Resistance?

What are the Symptoms of Ebola?

Can Flaviviridae infections be prevented?

How Can Adverse Effects be Minimized?

How Do Human Activities Amplify These Effects?

What is Bovine Tuberculosis?

Can Inherited Immunity Be Enhanced?

When Should You See a Doctor?

What is Veterinary Medicine?

Partnered Content Networks

Relevant Topics